

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): June 10, 2022**

**Vaccinex, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-38624**  
(Commission  
File Number)

**16-1603202**  
(IRS Employer  
Identification No.)

**1895 Mount Hope Avenue, Rochester, New York**  
(Address of principal executive offices)

**14620**  
(Zip Code)

**(585) 271-2700**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	VCNX	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

Vaccinex, Inc. (the "Company") will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time. A copy of the corporate presentation that will accompany the presentation is furnished to this Current Report on Form 8-K as Exhibit 99.1 and is available on the Company's website located at [www.vaccinex.com](http://www.vaccinex.com) under the heading "Investors" and subheading "Presentations."

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities under such section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1944, as amended, or the Exchange Act.

**Item 9.01 Financial Statements and Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">June 2022 corporate presentation of Vaccinex, Inc.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**VACCINEX, INC.**

Date: June 10, 2022

By: /s/ Scott E. Royer  
Scott E. Royer  
Chief Financial Officer

# Pepinemab – Anti-SEMA4D Antibody for Cancer Immunotherapy



**KEYNOTE-B84 Study  
in HNSCC**

June 10, 2022

## Forward Looking Statements

To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Such statements include, but are not limited to, statements about the Company’s plans, expectations and objectives with respect to the results and timing of clinical trials of pepinemab in various indications, the use and potential benefits of pepinemab in Head and Neck cancer, Huntington’s and Alzheimer’s disease and other indications, and other statements identified by words such as “may,” “will,” “appears,” “expect,” “planned,” “anticipate,” “estimate,” “intend,” “hypothesis,” “potential,” “advance,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of the Company’s research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, the risks related to the Company’s dependence on its lead product candidate pepinemab, the ability to leverage its ActivMAB® platform, the impact of the COVID-19 pandemic, and other matters that could affect the Company’s development plans or the commercial potential of its product candidates. Except as required by law, the Company assumes no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in the Company’s periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in the Company’s most recent year end Annual Report on Form 10-K and subsequent filings with the SEC.




# WHY DOES IMMUNE RESPONSE FAIL IN TUMORS?

## Immune Exclusion


Activated T-cells and dendritic cells can't penetrate tumor

Sema4D is expressed at tumor margin




● Tumor ● SEMA4D

Sema4D binds PLXN receptors on DCs and restricts penetration



● Tumor ● Dendritic Cells (CD11c)

T-cells are excluded from tumor



● CD8+ ● CD4+ T Cells

Pro-inflammatory cells are excluded from tumor and build up at the invasive edge

CD8 T cells align with Sema4D at the invasive edge of the tumor. Most of these excluded T-cells express Sema4D.

Dendritic Cells express receptors for SEMA4D and are heavily excluded at the invasive edge.

Human metastatic colorectal tumor, in collaboration with Emory University (NCT03373188)

# UNIQUE MECHANISM

Pepinemab:

1




↑ cytotoxic T cells

2




↓ inhibitory suppressor cells

**No treatment**  
Low CD8+ T cells  
High Tumor content and MDSC



Myeloid Derived Suppressor Cells (MDSC)

**Pepinemab**  
High CD8+ T cells  
Low tumor content and MDSC



Tumor CD8+ T cells

**Biopsies from patients with metastatic MSS Colorectal Cancer**

*Human metastatic colorectal tumor, in collaboration with Winship Cancer Institute, Emory University integrated biomarker study (NCT03373188), Wu et al. Ann Surg Oncol. 2021*



# RATIONALE FOR TREATMENT OF HNSCC

## Head and Neck cancer (HNSCC)


- Data suggest that SEMA4D is strongly expressed in HNSCC & induces high levels of myeloid derived suppressor cells (MDSC)
- Relatively low (17-19%) response rate to immune checkpoint therapy in HNSCC




**Hypothesis:** Inhibiting MDSC with pepinemab may enhance response to pembrolizumab in HNSCC



● Myeloid Derived Suppressor Cells (MDSC)




NSCLC



HNSCC

MDSC Density  
NSCLC vs HNSCC





# KEYNOTE B84 HEAD AND NECK CANCER TRIAL

- All patients receive standard of care Keytruda®, plus pepinemab for first-line treatment
- Ph1b Safety: COMPLETE
  - Appeared to be well tolerated
  - RP2D: 20mg/kg pepi and 200mg pembro, Q3W
- Ph2 Expansion: Accruing
- 17 of 18 sites in USA now actively enrolling
- Open-label, continuous monitoring



KEYNOTE B84: pepinemab + Keytruda® for first-line treatment of recurrent or metastatic head and neck cancer




## KEYNOTE-B84:

### Case studies to illustrate differences in positive response profiles

	Biopsy	Scans			Biomarkers	Adverse Events
	week 5	week 9	week 15	week 21		
<b>Case Study # 1: CR (confirmed)</b> <i>Oropharyngeal cancer</i> <i>Target lesions: metastases to lung</i> <i>(Left 11mm, Right 15mm)</i>	NO malignancy	19% decrease, SD	100% decrease, CR	Confirmed, CR Now 42 Weeks	PD-L1 CPS<20  HPV negative	<i>none of notable severity</i>
<b>Case Study # 2: CR (confirmed)</b> <i>Larynx cancer with direct invasion into thyroid and neck</i> <i>Target lesions: neck mass (37mm)</i>	NO malignancy	100% decrease, CR	Confirmed, CR	Continued CR Now 27 Weeks	PD-L1 CPS<1  HPV negative	<i>Grade 1 rash</i>
<b>Case Study # 4: PR (unconfirmed)</b> <i>Oropharyngeal cancer</i> <i>Target lesions: metastases to lung</i> <i>(Left 24 mm, Right 23 mm)</i>	Not available	6% decrease, SD	72% decrease, PR	Anticipated July '22	PD-L1 CPS≥20  HPV negative	<i>none of notable severity</i>

# KEYNOTE B84 Site Map

Total of 18 sites planned



# Pepinemab – Anti-SEMA4D Antibody for Huntington’s and Alzheimer’s Disease




Unique Targets

Novel Mechanisms

New Medicines

# SEMA4D IS UPREGULATED IN NEURONS DURING ALZHEIMER'S AND HUNTINGTON'S DISEASE PROGRESSION



Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity


Elizabeth E Evans, Vikas Mishra, Crystal Mallow, Elaine Gersz, Leslie Balch, Alan Howell, Ernest S. Smith, Terrence L. Fisher, Maurice Zauderer\*  
*Journal of Neuroinflammation, 2022, In Press.*

# COGNITIVE ASSESSMENT BATTERY (HD-CAB)

Co-Primary and pre-specified Exploratory analysis



HD-CAB Composite Index of 6 Cognitive Assessments



Andrew Feigin et al. *Nature Medicine*, 2022, *In Press*.



Two-item HD Cognitive Assessment: Pre-specified Co-Primary

LS Mean Difference Estimate (95% CI)	One-sided p-value	Favors Pepinemab	Critical value
<b>OTS:</b> -1.98 (-4.00, 0.05)	<b>0.028</b>	Yes	No [0.025]
<b>PTAP:</b> 1.43 (-0.37, 3.23)	<b>0.060</b>		

HD-CAB Composite Index: Pre-specified Exploratory





LS Mean Difference Estimate (95% CI)	One-sided p-value	Favors Pepinemab	Critical value
0.13 (0.03, 0.23)	<b>0.007</b>	Yes	Yes [0.025]

# COGNITIVE ASSESSMENT BATTERY (HD-CAB)

Exploratory and Post-hoc analysis



- “Learning effect” is lost when HD symptoms become manifest
- Pepinemab treatment restores the ability to benefit from experience (ie, to learn)




Pepinemab antibody blockade of SEMA4D in early Huntington’s Disease: the randomized, placebo-controlled, phase 2 SIGNAL trial  
 Andrew Feigin, Elizabeth E. Evans, Terrence L. Fisher, John E. Leonard, Ernest S. Smith, Alisha Reader, Vikas Mishra, Richard Manber, Kimberly A. Walters, Lisa Kowarski, David Oakes, Eric Siemers, Karl D. Kieburtz, Maurice Zauderer\*, and the Huntington Study Group SIGNAL investigators  
 Nature Medicine, 2022, In Press.






# ALZHEIMER'S DISEASE

## Phase 1b/2 Trial Design



NCT04381468

# Signal-AD Site Map





**INCORPORATED**  
2001



**HEADQUARTERS**  
Rochester, NY



**EMPLOYEES**  
39



**IPO NASDAQ VCNX**  
August 2018



**CAPITAL RAISE**  
**FEBRUARY 2021 \$32.0, JANUARY 2022 \$13.2 M**



**CASH BALANCE\***  
\$16.8 M



**SHARES OUTSTANDING\***  
42.66 M



**ANALYSTS**  
BTIG (T.Shrader)





Vaccinex, Inc. (Nasdaq: VCNX) is a publicly traded clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases with unmet medical needs, including cancer and neurodegenerative diseases.



\*as of 31MAR2022

# PIPELINE and MILESTONES



Research/Preclinical	Phase 1	Phase 2	Phase 3	Partner/Funding	Milestone
<b>Pepinemab Antibody Platform (anti-Semaphorin 4D Mab)</b>					
<b>Oncology</b>					
Pepinemab COMBO with Avelumab in Non Small Cell Lung Cancer		CLASSICAL-Lung		 	Complete, Published 2021
Pepinemab COMBO with Pembrolizumab in Head and Neck Cancer		KEYNOTE-B84			Ongoing Next data 2H 2022
<b>Neurology</b>					
Pepinemab in Huntington's Disease (Orphan Drug and Fast Track Designations)		SIGNAL		 	Complete, Nat. Med in press
Pepinemab in Alzheimer's Disease		SIGNAL-AD			Ongoing Data 2H 2023

All Studies Sponsored by:

